Max Healthcare Institute (543220) Q4 15/16 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 15/16 earnings summary
27 Oct, 2026Executive summary
FY 2015-16 standalone total income rose 14.8% YoY to ₹944.6 crore; consolidated total income was ₹1,475.2 crore vs ₹1,160.9 crore. Network expansion included Crosslay and Saket acquisitions.
Cash profit improved to ₹28.3 crore standalone from ₹11.3 crore; net loss narrowed to ₹22.2 crore from ₹38.1 crore. Consolidated loss before tax was ₹14.3 crore vs ₹37.1 crore.
Financial highlights
Standalone operating income was ₹914.9 crore vs ₹789.6 crore; operating profit was ₹58.2 crore vs ₹54.5 crore, while finance costs declined to ₹29.9 crore from ₹43.2 crore.
Consolidated operating income reached ₹1,445.4 crore vs ₹1,133.6 crore; operating profit was ₹145.4 crore vs ₹102.5 crore and cash profit ₹72.3 crore vs ₹41.3 crore.
Standalone EPS improved to -₹0.4 from -₹0.9; consolidated EPS improved to -₹0.3 from -₹0.8.
Outlook and guidance
Priorities include integrating acquired hospitals, strengthening existing operations, widening clinical offerings and leveraging the larger network to improve financial performance.
Productivity, occupancy, shorter inpatient stays and higher-complexity procedures are expected to support revenue realization and offset rising employee costs.
A three-year medical excellence plan targets clinical outcome tracking, fewer patient-safety incidents, selected-hospital JCIA accreditation and multidisciplinary care.
Latest events from Max Healthcare Institute
- Service mix and cost controls improved FY19 operations despite revenue and regulatory pressures.543220
Q4 18/19 - Operating growth and new funding advanced expansion, but losses and depreciation remained significant.543220
Q4 14/15 - Consolidated results returned to profit as hospital operations grew, despite pricing and cost pressures.543220
Q4 16/17 - Revenue advanced, but regulatory pressure and weaker operations drove FY18 losses.543220
Q4 17/18 - FY20 profitability rebounded as COVID disrupted activity and the Radiant merger expanded scale.543220
Q4 19/20 - Record FY22 performance funded a ~2,800-bed expansion pipeline.543220
Q4 21/22 - Operating EBITDA rose despite pandemic-led revenue pressure; QIP funding sharply reduced net debt.543220
Q4 20/21 - Revenue and EBITDA accelerated as expansion advanced and net cash strengthened.543220
Q4 22/23 - India's second largest hospital chain drives growth via metro expansion, digital health, and strong ESG.543220
Investor presentation